SOPHiA GENETICS
SOPH
32 hedge funds and large institutions have $40.1M invested in SOPHiA GENETICS in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 3 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 11
2.07% less ownership
Funds ownership: 32.48% → 30.41% (-2.1%)
6% less funds holding
Funds holding: 34 → 32 (-2)
27% less capital invested
Capital invested by funds: $54.7M → $40.1M (-$14.7M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$236K |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$225K |
| 3 |
MSAM
Moloney Securities Asset Management
Manchester,
Missouri
|
+$73K |
| 4 |
JP Morgan Chase
New York
|
+$68.3K |
| 5 |
BPC
Banque Pictet & Cie
Geneva 73,
Switzerland
|
+$34.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$2.31M |
| 2 |
Morgan Stanley
New York
|
-$952K |
| 3 |
PVI
Pura Vida Investments
New York
|
-$319K |
| 4 |
Principal Financial Group
Des Moines,
Iowa
|
-$152K |
| 5 |
AA
Alta Advisers
London,
United Kingdom
|
-$110K |
SOPH Hedge Fund Activity: Q4 2022 in Review
32 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in SOPHiA GENETICS (SOPH) for Q4 2022, worth a combined $40.1M — down 27% from $54.7M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of SOPH and 1 opened new positions — a net loss of 2 holders — while 11 trimmed existing stakes and 11 added.
The largest buyer was Credit Suisse, adding an estimated $236K. The largest seller was PFM Health Sciences, exiting entirely with an estimated $2.31M sold.
- 32 institutional investors held SOPHiA GENETICS (SOPH) as of Q4 2022, down from 34 in Q3 2022.
- Funds reported $40.1M of SOPHiA GENETICS stock for Q4 2022, down 27% quarter-over-quarter.
- 1 fund opened new SOPHiA GENETICS positions in Q4 2022 and 3 closed out, a net change of -2 holders.
- The largest SOPHiA GENETICS buyer in Q4 2022 was Credit Suisse, an estimated $236K added.
- The largest SOPHiA GENETICS seller in Q4 2022 was PFM Health Sciences, an estimated $2.31M sold.
Based on aggregated 13F filings for Q4 2022.